GOLGA6L10

Across TCGA pan-cancer cohorts, GOLGA6L10 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated GOLGA6L10 data layer compared with 17 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher GOLGA6L10 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated GOLGA6L10 expression acts as an unfavorable survival marker.

HNSC, BLCA, and OV are the cancer types where GOLGA6L10 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.087	0.710	<.001	36	view →
BLCA	OS	Median	All	0.187	0.720	.002	24	view →
OV	DFS	Median	All	0.132	0.541	.001	6	view →
UCEC	OS	Median	IV	0.308	0.748	.009	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

GOLGA6L10–HNSC (DFS)

Open the HNSC breakdown →